12 Month Price Forecast For DTIL
Distance to DTIL Price Forecasts
DTIL Price Momentum
๐ค Considering Precision BioSciences (DTIL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 9:26 PM UTC
DTIL Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, DTIL has a bullish consensus with a median price target of $30.00 (ranging from $19.00 to $60.00). Currently trading at $4.79, the median forecast implies a 526.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,152.6% upside. Conversely, the most conservative target is provided by Debjit Chattopadhyay at Guggenheim, suggesting a 296.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DTIL Analyst Consensus
DTIL Price Target Range
Latest DTIL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DTIL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 10, 2025 | BMO Capital | Kostas Biliouris | Outperform | Upgrade | $34.00 |
Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
Apr 30, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $19.00 |
Apr 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
Mar 28, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $60.00 |
Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
Sep 19, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
Aug 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $3.00 |
Aug 7, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $0.00 |
Jul 28, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Jul 28, 2023 | BTIG | Thomas Shrader | Buy | Maintains | $2.00 |
Jun 1, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
Mar 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
Mar 14, 2023 | BMO Capital | Kostas Biliouris | Market Perform | Downgrade | $4.00 |
Nov 10, 2022 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $17.00 |
Nov 10, 2022 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $1.00 |
Aug 9, 2022 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $2.00 |
Stocks Similar to Precision BioSciences Inc
The following stocks are similar to Precision BioSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Precision BioSciences Inc (DTIL) Financial Data
Precision BioSciences Inc has a market capitalization of $36.28M with a P/E ratio of 11.8x. The company generates $75.10M in trailing twelve-month revenue with a 11.5% profit margin.
Revenue growth is -95.6% quarter-over-quarter, while maintaining an operating margin of -3,693.6% and return on equity of +24.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Precision BioSciences Inc (DTIL) Company Overview
About Precision BioSciences Inc
Develops advanced gene editing therapies.
The company utilizes its proprietary ARCUS genome editing platform to create therapies that target genetic disorders through techniques such as gene insertion, deletion, and repair. It generates revenue through licensing agreements and collaborations with major pharmaceutical companies, as well as potential commercialization of its gene editing products.
Precision BioSciences has a diverse pipeline targeting various conditions, including chronic hepatitis B, mitochondrial myopathy, sickle cell disease, and Duchenne muscular dystrophy. The company has established partnerships with notable organizations like Eli Lilly and Novartis to enhance its research and development capabilities. Founded in 2006, it is based in Durham, North Carolina.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Michael Amoroso
Country
United States
IPO Year
2015
Website
www.precisionbiosciences.comPrecision BioSciences Inc (DTIL) Latest News & Analysis
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
13 days agoPrecision BioSciences (Nasdaq: DTIL) announced leadership enhancements and is advancing its PBGENE-HBV program through Phase 1 clinical trials, focusing on in vivo gene editing therapies.
Leadership changes and progress in clinical studies can signal potential growth and innovation, influencing investor confidence and stock performance in Precision BioSciences.
Precision BioSciences' partner iECURE announced positive clinical efficacy and safety data for the first patient treated with ECUR-506 in the Phase 1/2 OTC-HOPE study.
Positive clinical results from iECURE could enhance Precision BioSciences' partnership value, potentially leading to increased stock prices and investor interest in biotechnology advancements.
Precision BioSciences' partner iECURE reported clinical efficacy and safety data for ECUR-506 in the Phase 1/2 OTC-HOPE study, marking a significant development in gene editing therapies.
Positive clinical results for ECUR-506 enhance Precision BioSciences' reputation and potential market value, signaling advancements in gene therapy that could attract investment and partnerships.
iECURE, Inc. reported preliminary findings from the OTC-HOPE Phase 1/2 study of its gene therapy ECUR-506 for OTC deficiency, noting it was generally well tolerated in the first infant dosed.
Positive preliminary findings from iECURE's clinical trial for a novel gene therapy could indicate strong market potential and future revenue growth, attracting investor interest in biotech stocks.
Precision BioSciences received Clinical Trial Application approval in Hong Kong for its PBGENE-HBV program, aimed at curing chronic hepatitis B in the ongoing ELIMINATE-B Phase I trial.
Approval of the CTA for PBGENE-HBV indicates progress in Precision BioSciences' clinical trials, potentially boosting investor confidence and the company's valuation in the gene editing sector.
Precision BioSciences (Nasdaq: DTIL) will participate in the JonesTrading Virtual Genetic Medicine Day on November 25, 2024, focusing on advances in gene editing technologies.
Precision BioSciences' participation in investor conferences highlights its ongoing development in gene editing, potentially attracting interest and impacting stock performance.
Frequently Asked Questions About DTIL Stock
What is Precision BioSciences Inc's (DTIL) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Precision BioSciences Inc (DTIL) has a median price target of $30.00. The highest price target is $60.00 and the lowest is $19.00.
Is DTIL stock a good investment in 2025?
According to current analyst ratings, DTIL has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DTIL stock?
Wall Street analysts predict DTIL stock could reach $30.00 in the next 12 months. This represents a 526.3% increase from the current price of $4.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precision BioSciences Inc's business model?
The company utilizes its proprietary ARCUS genome editing platform to create therapies that target genetic disorders through techniques such as gene insertion, deletion, and repair. It generates revenue through licensing agreements and collaborations with major pharmaceutical companies, as well as potential commercialization of its gene editing products.
What is the highest forecasted price for DTIL Precision BioSciences Inc?
The highest price target for DTIL is $60.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,152.6% increase from the current price of $4.79.
What is the lowest forecasted price for DTIL Precision BioSciences Inc?
The lowest price target for DTIL is $19.00 from Debjit Chattopadhyay at Guggenheim, which represents a 296.7% increase from the current price of $4.79.
What is the overall DTIL consensus from analysts for Precision BioSciences Inc?
The overall analyst consensus for DTIL is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are DTIL stock price projections?
Stock price projections, including those for Precision BioSciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.